Table 4.
Univariate and multivariate analyses of prognostic factors for local control and freedom from distant progression.
| Variable | LC | FFWM |
|---|---|---|
| Age (y) (UVA Cox) | 0.94 | 0.81 |
| PRIMARY CANCER (UVA LOG RANK) | ||
| Colorectal, p | 0.38 | 0.30 |
| Lung, head/neck, esophagus, p | 0.20 | 0.50 |
| SITE INVOLVED (UVA LOG RANK) | ||
| Lung, p | 0.16 | 0.48 |
| Thoracic lymph nodes, p | 0.52 | 0.91 |
| Liver p | 0.12 | 0.25 |
| Number of oligometastatic lesions treated UVA (Cox), p | 0.90 | |
| Involved organs (1 vs. 2-3) UVA (Cox), p | 0.78 | |
| History of >5 metastases prior to enrollment (UVA Cox), p | 0.59 | 0.98 |
| Systemic therapy for metastasis (UVA Cox), p | 0.25 | 0.15 |
| MVA (Cox), p | 0.45 | 0.09 |
| BED≥75 GY | ||
| BED≥75 Gy (UVA Cox), p | <0.01 | 0.15 |
| UVA HR (95% CI) | 0.37 (0.18-0.76) | |
| MVA (Cox), p | 0.34 | 0.39 |
| MVA HR (95% CI) | 0.61 (0.23-1.68) | |
| History of prior curative local treatment (UVA Cox) | 0.25 | 0.97 |
| SUM OF GTV (CM3) | ||
| UVA (Cox), p | <0.01 | 0.14 |
| UVA HR (95% CI) per 10 cm3 | 1.09(1.05–1.13) | |
| MVA (Cox), p | <0.01 | 0.17 |
| MVA HR (95% CI) | 1.10 (1.04–1.16)/10cm3 | |